NASDAQ:CAPR Capricor Therapeutics (CAPR) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free CAPR Stock Alerts $4.82 -0.12 (-2.43%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$4.70▼$5.0250-Day Range$3.61▼$7.1052-Week Range$2.68▼$8.22Volume478,470 shsAverage Volume289,902 shsMarket Capitalization$151.83 millionP/E RatioN/ADividend YieldN/APrice Target$24.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Capricor Therapeutics alerts: Email Address Capricor Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside397.9% Upside$24.00 Price TargetShort InterestBearish11.11% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.13Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.83) to $0.12 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.75 out of 5 starsMedical Sector830th out of 910 stocksPharmaceutical Preparations Industry390th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingCapricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCapricor Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.11% of the outstanding shares of Capricor Therapeutics have been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.Change versus previous monthShort interest in Capricor Therapeutics has recently increased by 8.36%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCapricor Therapeutics does not currently pay a dividend.Dividend GrowthCapricor Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CAPR. Previous Next 1.0 News and Social Media Coverage News SentimentCapricor Therapeutics has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Capricor Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for CAPR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.00% of the stock of Capricor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of Capricor Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Capricor Therapeutics are expected to grow in the coming year, from ($0.83) to $0.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Capricor Therapeutics is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Capricor Therapeutics is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapricor Therapeutics has a P/B Ratio of 6.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Capricor Therapeutics Stock (NASDAQ:CAPR)Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Read More CAPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CAPR Stock News HeadlinesApril 19, 2024 | markets.businessinsider.comNurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative MedicineApril 17, 2024 | americanbankingnews.comCapricor Therapeutics (NASDAQ:CAPR) Share Price Passes Above 50-Day Moving Average of $5.44April 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 10, 2024 | finance.yahoo.comWall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should KnowApril 3, 2024 | investing.comCapricor Therapeutics Inc (CAPR)March 21, 2024 | globenewswire.comCapricor Therapeutics to Present at Upcoming Investor ConferencesMarch 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cyclo Therapeutics on Strong Clinical and Financial ProspectsMarch 14, 2024 | finance.yahoo.comEarnings Beat: Capricor Therapeutics, Inc. (NASDAQ:CAPR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 12, 2024 | markets.businessinsider.comBuy Rating Affirmed: Lineage Therap’s Growth and Innovation Poised to Transform Biotech LandscapeMarch 6, 2024 | markets.businessinsider.comCapricor Therapeutics: Strong Buy Rating Backed by Robust Financials and Promising Clinical ProgressMarch 6, 2024 | globenewswire.comCapricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceMarch 3, 2024 | finance.yahoo.comCapricor Therapeutics Full Year 2023 Earnings: Beats ExpectationsMarch 3, 2024 | seekingalpha.comCapricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comCapricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comQ4 2023 Capricor Therapeutics Inc Earnings CallFebruary 29, 2024 | benzinga.comRecap: Capricor Therapeutics Q4 EarningsFebruary 29, 2024 | finance.yahoo.comCapricor Therapeutics Inc (CAPR) Reports Encouraging Year-End Financials and Advances in DMD TherapyFebruary 29, 2024 | globenewswire.comCapricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | benzinga.comCapricor Therapeutics's Earnings OutlookFebruary 28, 2024 | markets.businessinsider.comCapricor Therapeutics is about to announce earnings — here's what Wall Street expectsFebruary 27, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE), Rocket Pharmaceuticals (RCKT)February 27, 2024 | markets.businessinsider.comCapricor Therapeutics Granted Type-B Meeting With FDA For CAP-1002 Muscular Dystrophy Drug, Stock UpFebruary 27, 2024 | marketwatch.comCapricor Therapeutics Shares Rise 8% After FDA Meeting SetFebruary 27, 2024 | globenewswire.comCapricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular DystrophyFebruary 22, 2024 | finance.yahoo.comCapricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29February 22, 2024 | globenewswire.comCapricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29See More Headlines Receive CAPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CAPR CUSIPN/A CIK1133869 Webwww.capricor.com Phone310-358-3200Fax415-875-7075EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$24.00 High Stock Price Target$40.00 Low Stock Price Target$8.00 Potential Upside/Downside+397.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,290,000.00 Net Margins-88.52% Pretax Margin-88.52% Return on Equity-299.67% Return on Assets-45.54% Debt Debt-to-Equity RatioN/A Current Ratio1.63 Quick Ratio1.63 Sales & Book Value Annual Sales$25.18 million Price / Sales6.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book6.60Miscellaneous Outstanding Shares31,500,000Free Float27,723,000Market Cap$151.83 million OptionableOptionable Beta3.99 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesFrank I. Litvack M.D. (Age 59)Independent Executive Chairman of the Board Linda Marban Ph.D. (Age 51)President, Chief Executive Officer, Director Anthony Bergmann (Age 32)Chief Financial Officer, Principal Accounting Officer Karen G. Krasney J.D. (Age 62)Executive Vice President, General Counsel Thomas Lyle Copmann Ph.D. (Age 61)Vice President - Regulatory Affairs and Drug Development Houman Hemmati M.D.Ph.D., Vice President - Medical & Clinical Development, New TherapiesLuis Rodriguez-Borlado Ph.D.Vice President - Regenerative TherapiesRachel Smith Ph.D. (Age 36)Vice President - Research & Development Deborah Ascheim M.D.Chief Medical OfficerJoshua A. Kazam (Age 40)Director More ExecutivesKey CompetitorsAlimera SciencesNASDAQ:ALIMGreenwich LifeSciencesNASDAQ:GLSI23andMeNASDAQ:MEGossamer BioNASDAQ:GOSSTrevi TherapeuticsNASDAQ:TRVIView All CompetitorsInsiders & InstitutionsJump Financial LLCBought 52,800 shares on 2/7/2024Ownership: 0.171%Simplex Trading LLCSold 2,900 shares on 2/2/2024Ownership: 0.000%David B MusketBought 410 shares on 10/12/2023Total: $1,127.50 ($2.75/share)David B MusketBought 5,083 shares on 10/9/2023Total: $14,334.06 ($2.82/share)Paul Gisbert AuwaerterBought 5,000 shares on 10/6/2023Total: $14,200.00 ($2.84/share)View All Insider TransactionsView All Institutional Transactions CAPR Stock Analysis - Frequently Asked Questions Should I buy or sell Capricor Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CAPR shares. View CAPR analyst ratings or view top-rated stocks. What is Capricor Therapeutics' stock price target for 2024? 2 equities research analysts have issued 1-year price targets for Capricor Therapeutics' stock. Their CAPR share price targets range from $8.00 to $40.00. On average, they expect the company's share price to reach $24.00 in the next year. This suggests a possible upside of 397.9% from the stock's current price. View analysts price targets for CAPR or view top-rated stocks among Wall Street analysts. How have CAPR shares performed in 2024? Capricor Therapeutics' stock was trading at $4.89 at the beginning of 2024. Since then, CAPR shares have decreased by 1.4% and is now trading at $4.82. View the best growth stocks for 2024 here. When is Capricor Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CAPR earnings forecast. How were Capricor Therapeutics' earnings last quarter? Capricor Therapeutics Inc (NASDAQ:CAPR) posted its earnings results on Thursday, February, 29th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.21. The biotechnology company had revenue of $12.09 million for the quarter, compared to the consensus estimate of $5.80 million. Capricor Therapeutics had a negative trailing twelve-month return on equity of 299.67% and a negative net margin of 88.52%. What ETF holds Capricor Therapeutics' stock? iShares Neuroscience and Healthcare ETF holds 2,030 shares of CAPR stock, representing 0.30% of its portfolio. What other stocks do shareholders of Capricor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD). How do I buy shares of Capricor Therapeutics? Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CAPR) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryGreat Crypto BullWeiss RatingsThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
